BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li B, Yang K, Liang D, Jiang C, Ma Z. Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors. Eur J Med Chem 2021;209:112940. [PMID: 33328099 DOI: 10.1016/j.ejmech.2020.112940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kargbo RB. Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS Med Chem Lett 2023. [DOI: 10.1021/acsmedchemlett.2c00543] [Reference Citation Analysis]
2 Iwasa Y, Iwata K, Okuno M, Sugiyama A, Nishigaki Y, Ohashi Y, Tanaka T, Iwashita T, Shimizu M, Tomita E. A Case of Early-Stage Gallbladder Cancer, Positive for ALDH1A1, Which Arose from Adenomyomatosis of the Gallbladder. Diagnostics 2022;12:2721. [DOI: 10.3390/diagnostics12112721] [Reference Citation Analysis]
3 Feng Z, Hom ME, Bearrood TE, Rosenthal ZC, Fernández D, Ondrus AE, Gu Y, McCormick AK, Tomaske MG, Marshall CR, Kline T, Chen CH, Mochly-Rosen D, Kuo CJ, Chen JK. Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1. Nat Chem Biol 2022. [PMID: 35788181 DOI: 10.1038/s41589-022-01048-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu J, Peng Y, Inuzuka H, Wei W. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.07.001] [Reference Citation Analysis]
5 Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y, Zhou Y. ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism. Front Oncol 2022;12:918778. [DOI: 10.3389/fonc.2022.918778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang D, Hao W, Li X, Han P, Niu Q. Aldh1a1 and Scl25a30 in diaphragmatic dysfunction. Exp Biol Med (Maywood) 2022;:15353702221085201. [PMID: 35410502 DOI: 10.1177/15353702221085201] [Reference Citation Analysis]
7 Caminear MW, Harrington BS, Kamdar RD, Kruhlak MJ, Annunziata CM. Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells. Front Oncol 2022;12:762820. [DOI: 10.3389/fonc.2022.762820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Dancik GM, Voutsas IF, Vlahopoulos S. Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia. Mol Biol Rep 2022. [PMID: 35028852 DOI: 10.1007/s11033-021-07073-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Omran Z. Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors. Molecules 2022;27:480. [PMID: 35056791 DOI: 10.3390/molecules27020480] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Llorach-Pares L, Nonell-Canals A, Avila C, Sanchez-Martinez M. Computer-Aided Drug Design (CADD) to De-Orphanize Marine Molecules: Finding Potential Therapeutic Agents for Neurodegenerative and Cardiovascular Diseases. Mar Drugs 2022;20:53. [PMID: 35049908 DOI: 10.3390/md20010053] [Reference Citation Analysis]
11 Dancik GM, Voutsas IF, Vlahopoulos S. Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.. [DOI: 10.1101/2021.10.20.21265241] [Reference Citation Analysis]